Array Biopharma Inc news

   Watch this stock
Showing stories 1 - 10 of about 85   

Articles published

ARRY 7.16 -0.30 (-4.02%)
price chart
Does This 50% Price Target Hike For Array BioPharma Inc. Make Sense?
What: Shares of Array BioPharma (NASDAQ: ARRY ) , a biopharmaceutical company focused on developing novel small molecule cancer drugs, surged just shy of 10% on Monday following a hefty price target hike from brokerage firm Stifel Nicolaus.
Array BioPharma Inc. (ARRY) Soared To A New High After Encorafenib Acquisition  RTT News
Array BioPharma To Report Financial Results For The Second Quarter Of Fiscal ...  MarketWatch
Why Array Biopharma Inc's Shares Skyrocketed
Although we don't believe in timing the market or panicking over market movements, we do like to keep an eye on big changes -- just in case they're material to our investing thesis.
Drug News Shoots Array BioPharma Inc. (ARRY) Higher, Bulls Swarm  Schaeffers Research (blog)
Array Biopharma (ARRY) to Acquire Global Encorafenib Rights from Novartis ...  StreetInsider.com
Array Biopharma Inc. (NASDAQ:ARRY) Share Rose by almost 10%
Array Biopharma Inc. (NASDAQ:ARRY) was a big mover last session, as the company saw its shares rise by almost 10% on the day.
Update: Array Biopharma Inc Short Interest Disclosure  Bar and Graph Report
Array Biopharma Inc Analyst Rating Update  Stafford Daily
Today's Perilous Reversal Stock: Array BioPharma (ARRY)
Array BioPharma Inc., a biopharmaceutical company, focuses on the discovery, development, and commercialization of small molecule drugs to treat patients with cancer in North America, Europe, and the Asia Pacific.
Biotech Stocks Technical Analysis - Achillion Pharma, Array BioPharma, Rexahn ...
The stock moved between $6.86 and $7.93 during the session. Array BioPharma Inc.'s shares have rallied 64.66% in the previous three trading sessions and 116.81% in the last three months.
Brokerage Firm Price Target on Array Biopharma Inc
Brokerage firm Jefferies maintains its rating on Array Biopharma Inc (NASDAQ:ARRY). As per the latest information, the brokerage house raises the price target to $9 per share from a prior target of $7.
Closing Bell Reports: Penn National Gaming Inc. (PENN), Array BioPharma, Inc ...  WallStreet Scope
Wednesday Stock Updates: Penn National Gaming Inc , Array Biopharma Inc ...  Rock Hill Daily
Short Interest of Array Biopharma Inc Drops by 2.4%
The short interest in Array Biopharma Inc (NASDAQ:ARRY) has declined from 18,577,143 on December 31,2014 to 18,129,117 on January 15,2015.
Array BioPharma (ARRY) Jumps: Stock Adds 9.8% in Session
Array BioPharma, Inc. (ARRY - Snapshot Report) was a big mover last session, as the company saw its shares rise by almost 10% on the day.
Why Starbucks Corporation (SBUX), Pandora Media Inc (P), and Array ...
... finishing just above the breakeven mark. However, while most sectors were in the red today, Starbucks Corporation (NASDAQ:SBUX), Pandora Media Inc (NYSE:P) and Array Biopharma Inc (NASDAQ:ARRY) beat the market by a mile to sit among the day's ...
Array Biopharma (ARRY) Scheduled to Post Earnings on Tuesday
Array BioPharma Inc is a biopharmaceutical company focused on the discovery, development and commercialization of small molecule drugs to treat patients afflicted with cancer and inflammatory diseases.
Stock News - Array Biopharma (ARRY),SGS (SGSOY),Standard Pacific (SPF ...  Techsonian (press release)
Healthcare Sector Movers: St. Jude Medical Inc. (STJ), Array BioPharma, Inc ...  WallStreet Scope